ArticlePloS one2024
Phytochemical screening, antioxidant and anti-Parkinson activities of Berula erecta: A novel medicinal plant.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plants, Pills, and the Brain: Exploring Phytochemicals and Neurological Medicines.International journal of plant, animal and environmental sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berula erecta L. is traditionally used for the treatment of various human ailments. The present project was arranged to study the antioxidant and anti-Parkinson efficacy of B. erecta extracts against rotenone-induced Parkinson diseases in rats. Fine powder of the plant was extracted with methanol and then fractionated through various solvents with increasing order of polarity. Phytochemical screenings were done using standard protocols and High-performance liquid chromatography (HPLC) while in-vitro antioxidant activities of plant fractions were evaluated using different free radicals. In-vivo anti-Parkinson and oxidative dysfunction experiments were conducted in rats. Results revealed that various fractions possessed flavonoids, alkaloids, terpenoids saponins, tannin, anthraquinon, and phlobatanine, while terpeniods and alkaloids were absent in aqueous fraction. Chromatographic analysis of methanol fraction showed the presence of various bioactive compounds viz., vitexin, orientin, rutin, catechin and myricetin. In-vitro antioxidant activities of various fractions of Berula erecta (B.erecta) showed that methanol fraction has remarkable scavenging efficacy of 2,2-Diphenyl-1-picrylhydrazyl (DPPH), beta carotene, and superoxide free radicals followed by chloroform fraction. Free radicals produced by 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid (ABTS), Hydrogen peroxide (H2O2), and hydroxyl free radicals were considerably scavenged by methanol fraction followed by ethyl acetate fractions. In-vivo study of animal model showed that methanol fraction has significant recovery effects at behavioural, physiological and biochemical level against rotenone induced Parkinson disease. B.erecta has significantly improved rotenone-induced motor and nonmotor deficits (depression and cognitive impairments), increased antioxidant enzyme activity, and reduced neurotransmitter changes. It has been concluded from the present data that B.erecta enhances neurotransmitter levels by alleviating oxidative stress and antioxidant enzyme activity, hence improving motor activity, cognitive functioning, and decreasing depressed behavior. These data suggest that B. erecta may be a promising medicinal agent for reducing the risk and progression of Parkinson's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.